Terns Pharmaceuticals Inc [NASDAQ: TERN] price surged by 13.30 percent to reach at $3.0.
A sum of 8268205 shares traded at recent session while its average daily volume was at 2.28M shares. Terns Pharmaceuticals Inc shares reached a high of $26.05 and dropped to a low of $22.63 until finishing in the latest session at $25.56.
The one-year TERN stock forecast points to a potential upside of 6.03. The average equity rating for TERN stock is currently 1.09, trading closer to a bullish pattern in the stock market.
Guru’s Opinion on Terns Pharmaceuticals Inc [TERN]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for TERN shares is $27.20 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on TERN stock is a recommendation set at 1.09. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
H.C. Wainwright have made an estimate for Terns Pharmaceuticals Inc shares, keeping their opinion on the stock as Buy, with their previous recommendation back on November 04, 2025. The new note on the price target was released on November 03, 2025, representing the official price target for Terns Pharmaceuticals Inc stock. Previously, the target price had yet another raise to $20, while Truist analysts kept a Buy rating on TERN stock.
The Price to Book ratio for the last quarter was 7.87, with the Price to Cash per share for the same quarter was set at 3.28.
TERN Stock Performance Analysis:
Terns Pharmaceuticals Inc [TERN] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 33.68. With this latest performance, TERN shares gained by 203.92% in over the last four-week period, additionally plugging by 711.43% over the last 6 months – not to mention a rise of 361.37% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for TERN stock in for the last two-week period is set at 92.39, with the RSI for the last a single of trading hit 1.98, and the three-weeks RSI is set at 1.43 for Terns Pharmaceuticals Inc [TERN]. The present Moving Average for the last 50 days of trading for this stock 10.48, while it was recorded at 21.95 for the last single week of trading, and 5.77 for the last 200 days.
Terns Pharmaceuticals Inc (TERN) Capital Structure & Debt Analysis
According to recent financial data for Terns Pharmaceuticals Inc. ( TERN), the Return on Equity (ROE) stands at -29.12%, highlighting a negative impact on investor capital. The Return on Assets (ROA) is -27.78%, reflecting the company’s efficiency in generating profits from its assets. Additionally, Terns Pharmaceuticals Inc’s Return on Invested Capital (ROIC) is -33.18%, showcasing its effectiveness in deploying capital for earnings.
Terns Pharmaceuticals Inc (TERN) Efficiency & Liquidity Metrics
Based on Terns Pharmaceuticals Inc’s (TERN) latest financial statements, the Debt-to-Equity Ratio is 0.00%, indicating its reliance on debt financing relative to shareholder equity.
Terns Pharmaceuticals Inc (TERN) Efficiency & Liquidity Metrics
From an operational efficiency perspective, Terns Pharmaceuticals Inc. (TERN) effectively leverages its workforce, generating an average of -$1600677.97 per employee. The company’s liquidity position is robust, with a Current Ratio of 19.52% and a Quick Ratio of 19.52%, indicating strong ability to cover short-term liabilities.
TERN Stock EPS
With the latest financial reports released by the company, Terns Pharmaceuticals Inc posted -0.24/share EPS, while the average EPS was predicted by analysts to be reported at -0.3/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 0.06. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for TERN. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Terns Pharmaceuticals Inc go to -7.42%.
Terns Pharmaceuticals Inc [TERN] Institutonal Ownership Details
There are presently around $97.40%, or 97.68%% of TERN stock, in the hands of institutional investors. The top three institutional holders of TERN stocks are: ORBIMED ADVISORS LLC with ownership of 7.62 million shares, which is approximately 10.2326%. VIVO CAPITAL, LLC, holding 6.18 million shares of the stock with an approximate value of $$42.11 million in TERN stocks shares; and VIVO CAPITAL, LLC, currently with $$41.54 million in TERN stock with ownership which is approximately 8.1923%.
